Market revenue in 2023 | USD 767.5 million |
Market revenue in 2030 | USD 1,083.8 million |
Growth rate | 5.1% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 59.92% in 2023. Horizon Databook has segmented the Japan inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
The approval of new treatments for Crohn’s disease and ulcerative colitis, developed by local players, is anticipated to fuel the market growth in Japan. For instance, in May 2019, Takeda Pharmaceutical Company Limited received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Entyvio (vedolizumab) for the treatment of Crohn’s disease.
Moreover, various factors like improved infrastructure, favorable regulations, and government focus on development of novel treatment options, such as introduction of biosimilars in the market, are factors expected to drive the market.
An increase in R&D activities to develop biosimilars in the country is expected to drive the market. For instance, a Japan-based company Fujifilm Kyowa developed a biosimilar reference to Humira (adalimumab).
Horizon Databook provides a detailed overview of country-level data and insights on the Japan inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Japan inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account